Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (41-50 of 275) with videos related to

Pageof 28
Sort By:
Drugs|June 21, 2012
Prognostic and predictive value of K-RAS mutations in non-small cell lung cancerRaffaele Califano, Lorenza Landi, Federico Cappuzzo
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Annals of Translational Medicine|April 19, 2018
Lung Cancer Update 2017: from the test tube to the bedLuca Bertolaccini, Federico Cappuzzo, Piergiorgio Solli
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2020
Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?Diego Cortinovis, Maria Gemelli, Federico Cappuzzo
International Journal of Molecular Sciences|August 26, 2022
<i>KRAS</i>-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future ChallengesSerena Ceddia, Lorenza Landi, Federico Cappuzzo
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging drugs for non-small cell lung cancerFederico Cappuzzo, Stefania Bartolini, Lucio Crinò
The New England Journal of Medicine|June 16, 2006
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancerFederico Cappuzzo, Lynne Bemis, Marileila Varella-Garcia
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Pageof 28

Showing results (41-50 of 275) with videos related to

Sort By:
Pageof 28
Drugs|June 21, 2012
Prognostic and predictive value of K-RAS mutations in non-small cell lung cancerRaffaele Califano, Lorenza Landi, Federico Cappuzzo
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Annals of Translational Medicine|April 19, 2018
Lung Cancer Update 2017: from the test tube to the bedLuca Bertolaccini, Federico Cappuzzo, Piergiorgio Solli
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2020
Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?Diego Cortinovis, Maria Gemelli, Federico Cappuzzo
International Journal of Molecular Sciences|August 26, 2022
<i>KRAS</i>-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future ChallengesSerena Ceddia, Lorenza Landi, Federico Cappuzzo
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging drugs for non-small cell lung cancerFederico Cappuzzo, Stefania Bartolini, Lucio Crinò
The New England Journal of Medicine|June 16, 2006
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancerFederico Cappuzzo, Lynne Bemis, Marileila Varella-Garcia
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Pageof 28